Biolinerx LTD. (BLRX) — 6-K Filings

All 6-K filings from Biolinerx LTD.. Browse 33 Foreign Current Report reports with AI-powered summaries and risk analysis.

6-K Filings (33)

BioLineRx Files Routine 6-K Foreign Issuer Report on March 26, 2026 — Mar 26, 2026
BioLineRx Ltd. filed a 6-K report on March 26, 2026, indicating a routine foreign issuer report. This filing, with accession number 0001178913-26-001738, includ
6-K Filing — Nov 24, 2025
6-K Filing — Nov 17, 2025
BioLineRx Ltd. Forms Joint Venture with Hemispherian AS — Sep 29, 2025 Risk: medium
On September 29, 2025, BioLineRx Ltd. entered into a joint venture with Hemispherian AS, a Norwegian corporation, for the development and clinical trials of a d
BioLineRx Ltd. Reports Q2 2025 Financial Results — Aug 14, 2025 Risk: medium
BioLineRx Ltd. announced its financial results for the three and six months ended June 30, 2025, on August 14, 2025. The company, incorporated in Israel, is a f
BioLineRx Ltd. Holds Annual Shareholder Meeting — Jun 30, 2025 Risk: low
BioLineRx Ltd. announced the results of its Annual General Meeting of Shareholders held on June 29, 2025. The meeting took place at 3:00 p.m. Israel time, and s
BioLineRx Ltd. Files Form 6-K Reporting Press Release — May 30, 2025 Risk: low
BioLineRx Ltd. filed a Form 6-K on May 30, 2025, to report a press release issued on the same date. The filing does not contain specific financial figures or op
BioLineRx Ltd. Reports Q1 2025 Financial Results — May 27, 2025 Risk: low
BioLineRx Ltd. announced its financial results for the three months ended March 31, 2025, on May 27, 2025. The company also published its unaudited interim cons
BioLineRx Sets Annual Shareholder Meeting for June 29 — May 23, 2025 Risk: low
BioLineRx Ltd. announced on May 23, 2025, that its Annual Meeting of Shareholders will take place on June 29, 2025, at 3:00 p.m. Israel time. The meeting will b
BioLineRx Ltd. Files Form 6-K Reporting Press Release — Jan 21, 2025 Risk: low
On January 21, 2025, BioLineRx Ltd. filed a Form 6-K to report the issuance of a press release. The filing itself does not contain the details of the press rele
BioLineRx Ltd. Files 6-K Report — Jan 17, 2025 Risk: low
On January 17, 2025, BioLineRx Ltd. filed a Form 6-K to report the issuance of a press release. This filing incorporates by reference the press release as Exhib
BioLineRx raises $50M in registered direct offering — Jan 7, 2025 Risk: medium
On January 6, 2025, BioLineRx Ltd. entered into a securities purchase agreement with certain institutional investors for a registered direct offering. The compa
BioLineRx Ltd. Files 6-K for ADS Sale — Jan 6, 2025 Risk: medium
On January 6, 2025, BioLineRx Ltd. announced the sale of 5,676,396 American Depositary Shares (ADSs), each representing fifteen ordinary shares. The company is
BioLineRx Ltd. Reports Q3 2024 Financial Results — Nov 25, 2024 Risk: low
BioLineRx Ltd. announced its financial results for the three and nine months ended September 30, 2024, on November 25, 2024. The company also published its unau
BioLineRx Licenses Technology to Ayrmid Pharma — Nov 21, 2024 Risk: medium
On November 20, 2024, BioLineRx Ltd. entered into a license agreement with Ayrmid Pharma Ltd. This agreement grants Ayrmid Pharma an exclusive, transferable, an
BioLineRx Gets 180-Day Nasdaq Bid Price Extension — Nov 12, 2024 Risk: medium
On November 12, 2024, BioLineRx Ltd. received a notification from Nasdaq indicating that the company has been granted an additional 180-day period to regain com
BioLineRx Ltd. Files Form 6-K — Nov 5, 2024 Risk: low
BioLineRx Ltd. filed a Form 6-K on November 5, 2024, to report the issuance of a press release. The filing itself does not contain the details of the press rele
BioLineRx Ltd. Files 6-K Reporting Press Release — Oct 16, 2024 Risk: low
BioLineRx Ltd. filed a Form 6-K on October 16, 2024, to report the issuance of a press release. The press release, filed as Exhibit 1, is incorporated by refere
BioLineRx Ltd. Reports Annual Shareholder Meeting Results — Oct 1, 2024 Risk: low
BioLineRx Ltd. announced the results of its Annual General Meeting of Shareholders held on October 1, 2024. The meeting took place at 3:00 p.m. Israel time, and
BioLineRx Sets Shareholder Meeting for October 1 — Aug 19, 2024 Risk: low
BioLineRx Ltd. announced on August 19, 2024, that its Annual Meeting of Shareholders will take place on October 1, 2024, at 3:00 p.m. Israel time. The meeting w
BioLineRx Ltd. Reports Q2 2024 Financial Results — Aug 15, 2024 Risk: medium
BioLineRx Ltd. announced its financial results for the three and six months ended June 30, 2024, on August 15, 2024. The company, headquartered at 2 HaMa'ayan S
BioLineRx Faces Breach of Contract Lawsuit — Jun 18, 2024 Risk: medium
On June 16, 2024, Biokine Therapeutics Ltd. filed a complaint against BioLineRx Ltd. in the District Court of Jerusalem, alleging breach of contract and a purpo
BioLineRx Acquires CrystaVix JAK1/2 Inhibitor Program — May 30, 2024 Risk: medium
BioLineRx Ltd. announced on May 30, 2024, that it has entered into a definitive agreement to acquire BioCryst Pharmaceuticals' CrystaVix program, a novel oral J
BioLineRx Ltd. Reports Q1 2024 Financial Results — May 28, 2024 Risk: low
BioLineRx Ltd. announced its financial results for the three months ended March 31, 2024, on May 28, 2024. The company also published its unaudited interim cons
BioLineRx Ltd. Files Form 6-K Announcing Press Release — May 24, 2024 Risk: low
On May 24, 2024, BioLineRx Ltd. issued a press release filed as Exhibit 1 to this Form 6-K. The filing itself does not contain substantive details beyond the an
BioLineRx Ltd. Files 6-K Report — May 17, 2024 Risk: low
BioLineRx Ltd. filed a Form 6-K on May 17, 2024, to report a press release issued on the same date. The filing incorporates this press release into its effectiv
BioLineRx Ltd. Files 6-K, Announces Press Release — May 6, 2024 Risk: low
On May 6, 2024, BioLineRx Ltd. (NASDAQ: BLRX) filed a Form 6-K to report the issuance of a press release. The press release, filed as Exhibit 1, details informa
BioLineRx Ltd. Files Form 6-K Reporting Press Release — Apr 17, 2024 Risk: low
BioLineRx Ltd. filed a Form 6-K on April 17, 2024, to report the issuance of a press release. The filing itself does not contain the details of the press releas
BioLineRx Ltd. Files March 2024 Report on Form 6-K — Apr 10, 2024 Risk: low
BioLineRx Ltd. announced on April 10, 2024, the issuance of a press release filed as Exhibit 1 to this Form 6-K. The press release is for the month of March 202
BioLineRx Ltd. Announces Registered Direct Offering — Apr 1, 2024 Risk: medium
On March 28, 2024, BioLineRx Ltd. entered into a definitive agreement for a registered direct offering with certain institutional investors. The filing does not
BioLineRx Ltd. Files 6-K, Incorporates Press Release — Mar 4, 2024 Risk: low
BioLineRx Ltd. filed a Form 6-K on March 4, 2024, to report the issuance of a press release. The press release, filed as Exhibit 1, is incorporated by reference
BioLineRx Files 6-K, Incorporates Press Release into Registrations — Feb 28, 2024 Risk: low
BioLineRx Ltd. filed a 6-K report on February 28, 2024, indicating the issuance of a press release on the same date. This press release, filed as Exhibit 1, has
BioLineRx Files 6-K, Issues Press Release on Feb 16 — Feb 16, 2024 Risk: low
BioLineRx Ltd. filed a Form 6-K on February 16, 2024, indicating it issued a press release on the same date. This filing, under Commission file number 001-35223

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX